Truist Financial analyst Srikripa Devarakonda maintains $Merck & Co (MRK.US)$ with a buy rating, and sets the target price at $132.
According to TipRanks data, the analyst has a success rate of 54.1% and a total average return of 13.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:
Expectations are set slightly above consensus for the upcoming Q3 sales, with particular attention on management's commentary regarding Gardasil and, to a lesser extent, Winrevair. While there's a positive outlook on Winrevair, it's anticipated that the resolution of the Gardasil issue in China may take some time, and it's uncertain whether sufficient clarity will be provided to alleviate investor concerns in this quarter.
The firm anticipates a tough quarter for the large-cap biopharmaceutical sector as part of an earnings preview.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
